Sandoz’s Position Opposing the Misuse of Our Medicines in the Administration of Capital Punishment
Sandoz’s mission is to discover new ways to improve and extend people’s lives. Our purpose is to contribute to society’s ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. While Sandoz takes no position on the death penalty itself, we object to the misuse of any of our products in the administration of capital punishment. Such misuse is fundamentally contrary to our mission and purpose.
Sandoz sells medicines that have important therapeutic uses, including medicines used in surgical procedures. Certain of these products have been identified by states for use in capital punishment, including some drugs which have never been used before in connection with lethal injections.
As a result, Sandoz has implemented distribution controls designed to prohibit the sale of such medicines to prisons and correctional facilities. Specifically, Sandoz has entered into contractual agreements with distributors stipulating that Sandoz medicines are to be sold exclusively to medical users such as hospitals for use consistent with approved product labeling. In addition, to prevent inappropriate diversion of our products, we have implemented similar contractual restrictions on any entity wishing to purchase such medicines for their own use, e.g., hospital or outpatient clinic.
Sandoz regularly monitors the distribution of our products to ensure compliance with our distribution controls and will take necessary legal action to ensure the proper use of our medicines.
Our corporate responsibility programs are an important part of how we help people around the world access high-quality medicine.
Despite the remarkable medical progress during the last century, there are still at least 400 million people worldwide who lack access to essential health services1 and more than two billion who cannot afford to buy the medicines they need2. A healthy life, unfortunately, is still far from a given for too many. Every year, eight million people die from cancer3 and 14 million new cases are diagnosed4. Nearly 10 million people develop tuberculosis (TB) annually, including one million children, and the disease claims 1.5 million victims per year5. Nearly half a million people still die of malaria every year6.
As a division of the Novartis Group, Sandoz is committed to playing a key role in achieving global healthcare goals, by pioneering new approaches to drive increased access worldwide. Increasing access to medicine is the basis of our day-to-day business model, but we also run a range of targeted corporate responsibility programs to ensure access for those most in need.
On the following pages, we explain more about the work we do on Corporate Responsibility and the programs we run. We focus on addressing specific health needs in underprivileged communities, including non-communicable and infectious diseases, as well as promoting access to medical information and capacity building through our maternal and child health and Breathe Africa programs. More details can be found by clicking on the links below.
Grants and Sponsorships
Sandoz Inc. A Novartis Division, is committed to supporting educational grants for Independent Medical Education (IME), Fellowships, Medical Sponsorships, Corporate Memberships, and other worthwhile initiatives to support a specific educational or professional development activity directed to medical healthcare professionals and the scientific community in order to improve patient health. In addition, Sandoz will support activities that address the needs of nonprofit 501(c)(3), 501(c)(4), and 501(c)(6) organizations, healthcare or healthcare related organizations and foundations efforts in educating and supporting patients, their family members, caregivers and the public and are consistent with the mission of Sandoz. Such programs aim to improve patient health and are fully compliant with all legal and regulatory guidelines and the ethical standards under which Sandoz conducts business.
Sandoz Position for Independent Medical Education
Providers can help to advance healthcare equity, address disparities in healthcare delivery for underrepresented and diverse populations, and create culturally sensitive content. Providers should consider implementing systems which positively influence the way in which education is delivered to ensure diversity and inclusion with respect to faculty selection (ensuring diversity in faculty selection), intended learners or target audience (planning for diversity of the intended audience and content), and education plan (ensuring that the plan is inclusive, culturally sensitive, and that all diverse groups’ data are included).
The Sandoz Office of Grants and Education (SOGE) will review all requests received for Professional Independent Medical Education Grants, Patient Advocacy Organization Grants, Medical Sponsorships and Corporate Membershipsthat may cover the following therapeutic areas of interest:
Please take the time to consider how your educational program fits within the therapeutic areas of interest mentioned above and the established regulations, laws and guidelines and that your request is submitted at least 60 calendar days prior to the start of the event to allow adequate time for processing.
While many more requests are received than can be funded, we regret that we cannot accommodate every request. However, your request will receive a fair review once all documentation is submitted.
Mail: Sandoz Office of Grants and Education, 100 College Rd West, Princeton NJ 08540
For additional questions, please refer to this FAQ
Investigator Initiated Trials
Sandoz supports independent Investigator Initiated Trials (IITs) which are studies with scientific and medical merit developed and sponsored by an independent Third Party Sponsor without any influence by Sandoz. For such studies Sandoz may only support the conduct of the study by providing financial support and/or supply of Sandoz product(s) in response to an unsolicited request submitted by the Third Party Sponsor.
Supported IITs can include studies conducted in human subjects and/or studies that require a subject’s consent; as well as non-clinical studies, where Sandoz is supporting the conduct of the study with provision of funds and/or Sandoz drug supply in response to a request from a Third Party Sponsor. Studies may be either interventional (Phase I to Phase IV and where Sandoz provides drug), or non-interventional (the study does not focus on a Sandoz drug, or it may focus on a Sandoz drug but Sandoz does not provide that drug).
Sandoz accepts applications from either institutions (academic or governmental) and individual investigators or groups of investigators.
There are instances where a patient has a serious or life-threatening disease or condition, for which all currently available treatment options have been exhausted and enrollment into a clinical trial is not possible. In these cases, the treating physician can request an investigational or pre-approval product prior to regulatory approval, provided it is allowed by the applicable local laws. Within Sandoz, A Novartis Division, we refer to such provision of investigational or pre-approval products as “Managed Access.”
The Sandoz “Managed Access” terminology covers all locally defined pre-approval access mechanisms and programs such as “Compassionate Use”, “Expanded Access”, “Named Patient Supply”, “Special Access Schemes/Programs”, “Authorizations temporaires d’utilisation (ATU)” and others.
Sandoz “Managed Access” addresses this need by making certain investigational or unapproved treatments available to eligible patients.
Please note that your request will be assessed in consideration of applicable local laws and regulations. Each request will be acknowledged immediately, and reviewed carefully and fairly by the appropriate Sandoz medical lead with every effort made to provide a response promptly once all the necessary information has been submitted.
In addition, since 2017 Novartis has collaborated with an external Independent Bioethics Advisory Committee (IBAC), which provides analysis and recommendations on Novartis guidelines and policies for the ethical conduct of clinical research, and on selected ethical challenges, which may arise in clinical trials, development programs and managed access programs. The IBAC is comprised of bioethicists, clinicians, healthcare practitioners, patient advocates and other domain knowledge experts appropriate to the problem at hand.